The JACC: Cardiovascular Interventions has published results of the SEATTLE II trial, a prospective, single-arm, multi-center trial designed to evaluate the safety and effectiveness of ultrasound-facilitated catheter-directed low-dose thrombolysis, using the EKOS EkoSonic Endovascular System.
The study concluded that treatment with ultrasound-facilitated catheter-directed low-dose thrombolysis for acute pulmonary embolism (PE) improves right heart function, reduces blood clot size, and decreases pulmonary hypertension in patients with intermediate to high risk PE, according to the device’s manufacturer, EKOS Corp.
Importantly, no patient experienced intracranial hemorrhage, a serious adverse experience related to full-dose thrombolysis treatment, EKOS noted.
- Disorders & Diseases
- Public Health
- Products & Treatment
- Department Management